Tag Archive for: EyeBio

The acquisition strengthens and diversifies Merck’s pipeline with the addition of Restoret, a novel late-phase candidate for diabetic macular edema and neovascular age-related macular degeneration, as well as preclinical candidates.

Today the company announced a deal worth $3 billion to buy EyeBio and its first-in-class trispecific antibody Restoret, marking the pharma’s return to the ophthalmology space after nearly a decade.